DONG-E-E-JIAO CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 69.79 CNY | -0.01% |
|
+3.07% | +41.50% |
| Sales 2024 * | 5.66B 781M | Sales 2025 * | 6.61B 912M | Capitalization | 44.94B 6.2B |
|---|---|---|---|---|---|
| Net income 2024 * | 1.41B 195M | Net income 2025 * | 1.66B 230M | EV / Sales 2024 * | 6.68 x |
| Net cash position 2024 * | 7.13B 983M | Net cash position 2025 * | 7.53B 1.04B | EV / Sales 2025 * | 5.66 x |
| P/E ratio 2024 * |
31.8
x | P/E ratio 2025 * |
27
x | Employees | 3,678 |
| Yield 2024 * |
2.85% | Yield 2025 * |
3.04% | Free-Float | 66.22% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.01% | ||
| 1 week | +3.07% | ||
| Current month | +3.07% | ||
| 1 month | -1.70% | ||
| 3 months | +17.41% | ||
| 6 months | +39.25% | ||
| Current year | +41.50% |
1 week
67.28
71.30
1 month
67.2872.91
Current year
47.3872.91
1 year
44.5272.91
3 years
27.6072.91
5 years
24.9272.91
10 years
24.9273.71
| Managers | Title | Age | Since |
|---|---|---|---|
Jie Cheng
PSD | President | 45 | 22-01-09 |
Hong Yan Ding
DFI | Director of Finance/CFO | 54 | 21-06-28 |
Rong Deng
BRD | Director/Board Member | 46 | 20-03-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Guang Li Liu
BRD | Director/Board Member | 60 | 08-06-29 |
De An Guo
BRD | Director/Board Member | 62 | 21-06-28 |
Guang Wei Wen
BRD | Director/Board Member | 61 | 21-06-28 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.48% | 1 M€ | -18.21% | - | |
| 0.11% | 1 M€ | +3.49% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-07 | 69.79 | -0.01% | 4,976,261 |
| 24-06-06 | 69.8 | +1.41% | 4,572,183 |
| 24-06-05 | 68.83 | -0.25% | 2,669,095 |
| 24-06-04 | 69 | +2.03% | 5,019,479 |
| 24-06-03 | 67.63 | -0.12% | 5,090,097 |
End-of-day quote Shenzhen S.E., June 06, 2024
More quotes
Dong-E-E-Jiao Co., Ltd. specializes in the manufacturing and marketing of Chinese traditional medicines and health products. The products are primarily for deficiencies in the blood, immunodeficiency, indigestion, insomnia and fatigue.
Sector
Pharmaceuticals
Calendar
2024-08-21
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
69.79
CNY
Average target price
77.86
CNY
Spread / Average Target
+11.56%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +41.50% | 6.2B | |
| -22.89% | 4.1B | |
| +9.36% | 3.41B | |
| -19.39% | 2.83B | |
| -11.05% | 2.29B | |
| +45.24% | 1.93B | |
| +46.81% | 1.51B | |
| -7.51% | 1.52B | |
| -18.04% | 1.49B | |
| -19.10% | 1.42B |
- Stock Market
- Equities
- 000423 Stock
